{
    "clinical_study": {
        "@rank": "159861", 
        "arm_group": {
            "arm_group_label": "Lu AE58054", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "To determine the absolute bioavailability of the Lu AE58054 tablet formulation at steady\n      state"
        }, 
        "brief_title": "Absolute Bioavailability of Lu AE58054 in Healthy Subjects", 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy men and women aged between 21-55 years (inclusive) and with an BMI in the\n             range 18.5 to 32 kg/m2 (minimum weight 60 kg for men and 55 kg for women).\n\n          -  The subjects CYP2D6 genotype must be determined before inclusion into the study.\n\n          -  Women must not be pregnant or lactating.\n\n        Exclusion Criteria:\n\n          -  The subject is, in the opinion of the investigator, unlikely to comply with the\n             protocol or is unsuitable for any reason.\n\n        Other inclusion and exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02019394", 
            "org_study_id": "14915A", 
            "secondary_id": "2012-005646-37"
        }, 
        "intervention": {
            "arm_group_label": "Lu AE58054", 
            "description": "Oral dosing: 90 mg Lu AE58054 as a single dose once and after a 3 days washout period, once daily for 7 days.\nIntravenous dosing: 90 \u03bcg/not more than (NMT) 1000 nCi/37 kBq 14C-Lu AE58054 for intravenous infusion once on Day 10.", 
            "intervention_name": "Lu AE58054", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 20, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Nottingham", 
                    "country": "United Kingdom", 
                    "zip": "NG11 6JS"
                }, 
                "name": "GB803"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "1", 
        "official_title": "Interventional, Open-label Study Investigating the Absolute Bioavailability of Lu AE58054 After Multiple Oral Dosing and a Single Radio-labelled Intravenous Micro-dose as Well as the Contribution of Cytochrome P450 2D6 to the Exposure of Lu AE58054 in Healthy Subjects", 
        "overall_official": {
            "affiliation": "LundbeckClinicalTrials@lundbeck.com", 
            "last_name": "Email contact via H. Lundbeck A/S", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Intravenous (IV)", 
                "measure": "Absolute bioavailability: (AUC0-24) Dose oral/(AUC0-inf) Dose IV", 
                "safety_issue": "No", 
                "time_frame": "Day 10"
            }, 
            {
                "description": "Poor Metaboliser (PM); Extensive Metaboliser (EM)", 
                "measure": "Ratio of (AUC0-24(PM)/AUC0-24(EM))", 
                "safety_issue": "No", 
                "time_frame": "Day 10"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02019394"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Standard clinical safety assessments", 
                "measure": "Number and frequency of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 16"
            }, 
            {
                "description": "Adverse event monitoring", 
                "measure": "Number of subjects with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 16"
            }, 
            {
                "description": "Columbia Suicide Severity Rating Scale (C-SSRS) categorisation based on Columbia Classification Algorithm of Suicide Assessment (C-CASA) definitions", 
                "measure": "Risk of Suicidality", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 16"
            }
        ], 
        "source": "H. Lundbeck A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "H. Lundbeck A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}